Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition

Phase 2 Completed 126 enrolled Biomed Industries, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 2 randomized, double-blind, placebo-controlled, parallel arm study of NA-931 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.

Timeline

Start: 2024-07-19
Primary completion: 2025-02-27
Completion: 2025-04-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NA-931	Peptide	—	Oral

Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition

Summary

Timeline

Drugs

Indications